Biomarkers of tumor-reactive CD4
Biomarkers, Tumor
Genital Neoplasms, Female
Immunotherapy, Adoptive
Lymphocytes, Tumor-Infiltrating
T-Lymphocytes
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
accepted:
25
11
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
3
1
2023
Statut:
ppublish
Résumé
Despite the growing interest in immunotherapeutic interventions for endometrial cancer (EC), the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in this tumor type remains unclear. To better understand the role of TILs in EC, we analyzed the phenotypic traits of CD8 We found that CD8 Our results demonstrate that EC are frequently infiltrated by tumor-reactive TILs, and that expression of PD-1
Sections du résumé
BACKGROUND
Despite the growing interest in immunotherapeutic interventions for endometrial cancer (EC), the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in this tumor type remains unclear.
METHODS
To better understand the role of TILs in EC, we analyzed the phenotypic traits of CD8
RESULTS
We found that CD8
CONCLUSIONS
Our results demonstrate that EC are frequently infiltrated by tumor-reactive TILs, and that expression of PD-1
Identifiants
pubmed: 36581331
pii: jitc-2022-005443
doi: 10.1136/jitc-2022-005443
pmc: PMC9806064
pii:
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AG is a member of the scientific advisory board (SAB) of Achilles Therapeutics, SingulaBIO, RootPath, and BioNTech SE, and consults for PACT Pharma, and Instil BIo. AG is co-inventor of patents licensed and with royalties related to this work E-059-2013/0, E-085-2013/0, E-149-2015/0. IM reports grants from Roche, BMS, AstraZeneca and Genmab, as well as consultancy activities for Roche, BMS, AZ, Phamamar, F-sar, Merus, Amunix, Pieris, Numab, Third Rock and Highlight therapeutics. The authors declare that no other conflict of interest exists.
Références
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
Nature. 2021 Aug;596(7870):126-132
pubmed: 34290408
Front Immunol. 2022 Jan 07;12:788959
pubmed: 35069566
Nat Commun. 2022 Mar 16;13(1):1373
pubmed: 35296668
Nat Biomed Eng. 2022 Feb;6(2):108-117
pubmed: 35087171
Science. 2022 Feb 25;375(6583):877-884
pubmed: 35113651
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Clin Cancer Res. 2017 May 15;23(10):2491-2505
pubmed: 27827318
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Clin Cancer Res. 2019 Apr 15;25(8):2537-2548
pubmed: 30523022
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35439168
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33332284
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
J Clin Med. 2020 Jun 03;9(6):
pubmed: 32503218
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35064011
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
J Exp Med. 2022 Feb 7;219(2):
pubmed: 34935874
Mod Pathol. 2022 Feb;35(2):256-265
pubmed: 34642425
Sci Transl Med. 2020 Jun 17;12(548):
pubmed: 32554706
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Gynecol Oncol. 2015 Jul;138(1):11-7
pubmed: 25931171
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Sci Adv. 2021 Feb 26;7(9):
pubmed: 33637530
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
Gynecol Oncol. 2017 Apr;145(1):200-207
pubmed: 28040204
Cancer Cell. 2022 Apr 11;40(4):393-409.e9
pubmed: 35413271
Sci Rep. 2020 Dec 9;10(1):21530
pubmed: 33299035
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Cancer Immunol Res. 2020 Oct;8(10):1311-1321
pubmed: 32759363
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Mod Pathol. 2019 Mar;32(3):396-404
pubmed: 30291344
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Oncoimmunology. 2014 May 29;3:e28976
pubmed: 25083325
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Eur J Cancer. 2016 Jun;60:1-11
pubmed: 27038842
Nature. 2022 May;605(7910):532-538
pubmed: 35508657
Nature. 2021 Aug;596(7870):119-125
pubmed: 34290406
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Eur J Immunol. 2022 Jan;52(1):96-108
pubmed: 34505280
Cancer Immunol Res. 2020 Dec;8(12):1508-1519
pubmed: 32999003
Cancer Cell. 2022 May 9;40(5):479-493.e6
pubmed: 35452604
Cancer Cell. 2022 Apr 11;40(4):410-423.e7
pubmed: 35413272